Advertisement
UK markets close in 2 hours 37 minutes
  • FTSE 100

    7,968.10
    +36.12 (+0.46%)
     
  • FTSE 250

    19,877.63
    +66.97 (+0.34%)
     
  • AIM

    744.03
    +1.92 (+0.26%)
     
  • GBP/EUR

    1.1690
    +0.0021 (+0.18%)
     
  • GBP/USD

    1.2643
    +0.0005 (+0.04%)
     
  • Bitcoin GBP

    56,068.69
    +264.89 (+0.47%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,253.52
    +5.03 (+0.10%)
     
  • DOW

    39,769.81
    +9.73 (+0.02%)
     
  • CRUDE OIL

    82.53
    +1.18 (+1.45%)
     
  • GOLD FUTURES

    2,227.10
    +14.40 (+0.65%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,495.05
    +17.96 (+0.10%)
     
  • CAC 40

    8,222.05
    +17.24 (+0.21%)
     

Insulin infusion device maker CeQur raises $100 mln

LONDON, Sept 1 (Reuters) - Privately held company CeQur, which is developing the world's first three-day insulin infusion device for people with type 2 diabetes, has raised $100 million in a funding round that shows strong investor appetite for hot medical technology.

The deal is the largest medical technology financing in Europe since 2006, according to its backers.

The Swiss-headquartered group said it would use the cash from the so-called series C financing to pay for clinical and regulatory work, as well as to scale up manufacturing and commercial operations ahead of the expected launch of its second-generation PaQ device in 2016.

The patch-like insulin infusion device offers an alternative to daily insulin injections made by the likes of Novo Nordisk (Other OTC: NONOF - news) , Sanofi (NasdaqGM: GCVRZ - news) and Eli Lilly.

ADVERTISEMENT

The new funding round was led by Woodford Investment Management and Arthurian Life Sciences. Existing investors including Endeavour Vision, Schroder & Co Banque and VI Partners also participated in the round.

CeQur was established in January 2008 and is chaired by Eric Milledge, who previously worked at Johnson & Johnson (NYSE: JNJ - news) for more than three decades. (Reporting by Ben Hirschler; Editing by Mark Potter)